Lamisil 250 mg tablete
| Name | Lamisil 250 mg tablete |
|---|---|
| Marketing Authorisation Number | HR-H-798097379 |
| Active Substance | terbinafinklorid |
| Composition | jedna tableta sadrži 250 mg terbinafina (u obliku terbinafinklorida) |
| Pharmaceutical Form | tableta |
| Manufacturer | Novartis Pharma GmbH, Nürnberg, Njemačka Lek Pharmaceuticals d.d., Lendava, Slovenija Novartis Farmacéutica S.A., Barcelona, Španjolska |
| Marketing Authorisation Holder | Novartis Hrvatska d.o.o., Radnička cesta 37b, Zagreb, Hrvatska |
| Marketing Authorisation Date | 04.09.2018 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/17-02/389 |
| Registration Number | 381-12-01/38-18-06 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | neponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | D01BA02 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
